Brad Margus is the co-founder and Board Chair of Cerevance, a neuroscience company leveraging transcriptional and epigenetic profiling of thousands of post-mortem human brain samples to develop treatments for brain diseases. He served as CEO from the company’s inception until 2022. The company’s lead program, CVN424, is now in a Phase 3 study for Parkinson’s Disease. Investors include Google Ventures, Bill Gates, Casdin Capital, Lightstone Ventures, Foresite Capital, UPMC Enterprises, Dolby Ventures, Agent Capital, and the Dementia Discovery Fund.

In 2013, Margus started Genome Bridge, a non-profit subsidiary of the Broad Institute of Harvard and M.I.T., to build a computational platform for sharing genomic data. From 2009 to 2012, as co-founder and CEO of Envoy Therapeutics, Margus led the discovery of therapeutics for brain diseases and sold the company to Takeda Pharmaceuticals. From 2000 to 2007, Margus was co-founder and CEO of Perlegen Sciences, a leader in analyzing genetic variation.

Concurrent with his business career, Margus has worked as a volunteer in leading the A-T Children’s Project, a non-profit he founded that funds research on a rare disease – ataxia telangiectasia or “A-T” – that two of his sons have. A-T causes progressive loss of muscle control, immune deficiency, lung problems and cancer.

Margus also currently serves on the Boards of Neurona, a cell therapy company; Tactile Therapeutics, advancing protein degraders and molecular glues for necroptosis; and Mind Immune, developing an antibody that blocks recruitment of immune cells into the brain. He also serves as Co-chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board at the NIH.

Margus previously served on the Boards of Arvinas (Nasdaq: ARVN), a protein degradation company; HC Bio, a TRNA company; Cellular Research, a molecular biology tool company (acquired by Becton Dickinson); Second Genome, a microbiome company; and Presage Biosciences, an oncology device company. He also served on the Advisory Council to the National Inst. of Neurological Disorders and Stroke; the Secretary of HHS’s Advisory Committee on Genetics, Health and Society; the Board of the Genetic Alliance, representing hundreds of genetic disease advocacy organizations; the Nat’l. Center for Advancing Translational Sciences Advisory Council at the NIH, the Cure Acceleration Network Review Board; as a Harvard Business School Global Advisor, as an advisor to Counsyl (acquired by Myriad Genetics); the Board of Children’s Neurobiological Solutions; the Board of Global Genes, a non-profit supporting all rare diseases; and on the Stanford University School of Medicine’s Stem Cell Research Oversight Committee. Margus holds an MBA from Harvard.